EUVIMEDEUVIMED entdecken
Crossref

Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma

Yinghong Hao, Wenzhi Zhu, Jie Li, Ruirui Lin, Wenting Huang, Qurat Ul Ain, Kaicai Liu, Ning Wei, Delei Cheng, Yi Wu, Weifu Lv

Journal of Controlled Release · 2024-08 · 372 · 155-167

DOI: 10.1016/j.jconrel.2024.06.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-08. Verfasst von Yinghong Hao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China…. Hauptthemen laut MEDLINE: Prodrugs, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transarterial chemoembolization (TACE) is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but facing the problem of low therapeutic effect. Conventional TACE formulations contain Lipiodol (LP) and chemotherapeutic agents characterized by burst release due to the unstable emulsion. Herein, we developed a novel TACE system by inducing bovine serum albumin (BSA) loaded hypoxia-activated prodrug (tirapazamine, TPZ) nanoparticle (BSATPZ) for sustained drug release. In the rabbit VX2 liver cancer model, TACE treatment induced a long-term hypoxic tumor microenvironment as demonstrated by increased expression of HIF-1α in the tumor. BSATPZ nanoparticles combined with LP greatly enhanced the anti-tumor effects of the TACE treatment. Compared to conventional TACE treatment, BSATPZ nanoparticle-based TACE therapy more significantly delayed tumor progression and inhibited the metastases in the lungs. The effects could be partially mediated by the rebuilt immune responses, as BSATPZ nanoparticle can served as an immunogenic cell death (ICD) inducer. Collectively, our results suggest that BSATPZ nanoparticle-based TACE therapy could be a promising strategy to improve clinical outcomes for patients with HCC and provide a preclinical rationale for evaluating TPZ therapy in clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsNanoparticlesSerum Albumin, BovineDelayed-Action PreparationsTirapazamineAntineoplastic AgentsAnimalsRabbitsEthiodized OilCell Line, TumorTumor MicroenvironmentMaleDrug LiberationHumans

Stichwörter der Autor:innen

Hepatocellular carcinomaHypoxic tumor microenvironmentImmune cell infiltrationSustained releaseTirapazamineTranscatheter arterial chemoembolization

Substanzen

ProdrugsSerum Albumin, BovineDelayed-Action PreparationsTirapazamineAntineoplastic AgentsEthiodized Oil

Autor:innen und Institutionen

  • Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
  • Department of Radiology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230001, China.
  • Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China; Institute of Health and Medicine, Hefei…
  • Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China. Electronic address: weifulv@ustc.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Hao, Y., Zhu, W., Li, J., Lin, R., Huang, W., Ain, Q. U., Liu, K., Wei, N., Cheng, D., Wu, Y., & Lv, W. (2024). Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma. Journal of Controlled Release, 372, 155-167. https://doi.org/10.1016/j.jconrel.2024.06.026

Vancouver

Hao Y, Zhu W, Li J, Lin R, Huang W, Ain QU, et al. Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma. Journal of Controlled Release. 2024;372:155-167. doi:10.1016/j.jconrel.2024.06.026

BibTeX
@article{Hao2024,
  author = {Hao, Yinghong and Zhu, Wenzhi and Li, Jie and Lin, Ruirui and Huang, Wenting and Ain, Qurat Ul and Liu, Kaicai and Wei, Ning and Cheng, Delei and Wu, Yi and Lv, Weifu},
  title = {Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {372},
  pages = {155--167},
  doi = {10.1016/j.jconrel.2024.06.026}
}
Kostenlos starten →